Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 529

Sort by

Sort Order Select

Journal Articles

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Blood (2020) 135 (26): 2402–2412.

https://doi.org/10.1182/blood.2019004492

Published: 2020

Includes: Supplemental data

Journal Articles

Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors

Paolo Strati, Ellen J. Schlette, Luisa M. Solis Soto, Daniela E. Duenas, Mariela Sivina, Ekaterina Kim, Michael J. Keating, William G. Wierda, Alessandra Ferrajoli, Hagop Kantarjian, Zeev Estrov, Nitin Jain, Philip A. Thompson, Ignacio I. Wistuba, Jan A. Burger

Blood (2020) 135 (7): 510–513.

https://doi.org/10.1182/blood.2019003570

Published: 2020

Journal Articles

Lactate Dehydrogenase to Carboxyhemoglobin Ratio As a Biomarker of Heme Release to Heme Processing Is Associated with Higher Tricuspid Regurgitant Jet Velocity and Early Death in Sickle Cell Disease

Annelies J. Van Vuren, MD, Laurel Mendelsohn, BS, Richard van Wijk, PhD, Caterina P. Minniti, MD, John Baird, MD, Gregory J Kato, MD, Eduard J. van Beers, MD PhD

Blood (2019) 134 (Supplement_1): 2274.

https://doi.org/10.1182/blood-2019-124048

Published: 2019

Journal Articles

Predictive Factors for Thrombopoietin Receptor Agonist Free Responses in Chronic ITP Patients: A Multicenter Retrospective Study with Long-Term Follow-up

Blood (2019) 134 (Supplement_1): 2370.

https://doi.org/10.1182/blood-2019-125580

Published: 2019

Journal Articles

Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Long-Term Follow up of the German Hodgkin Study Group (GHSG) HD14 Trial

Sarah Gillessen, MD, Annette Plütschow, Michael Fuchs, MD, Jana Markova, MD, Richard Greil, MD, Max S. Topp, MD, Julia Meissner, MD, Josée M Zijlstra, MD PhD, Dennis A. Eichenauer, Volker Diehl, MD, Peter Borchmann, MD PhD, Andreas Engert, MD, Bastian von Tresckow, MD

Blood (2019) 134 (Supplement_1): 129.

https://doi.org/10.1182/blood-2019-125249

Published: 2019

Journal Articles

RNA Sequencing in Childhood B-Lymphoblastic Leukemia Improves Molecular and Risk Assignment

Allen Eng Juh Yeoh, MD, Zhenhua Li, PhD, Shawn Lee, MD, Winnie Hui Ni Chin, Nan Jiang, PhD, Yi Lu, PhD, Shirley Kow Yin Kham, BSc, Ah Moy Tan, MD, Hai_peng Lin, Thuan Chong Quah, Hany Ariffin, Jun J. Yang, PhD

Blood (2019) 134 (Supplement_1): 651.

https://doi.org/10.1182/blood-2019-131653

Published: 2019

Journal Articles

Long Term Discontinuation of Eltrombopag after Remission in Primary Immune Thrombocytopenia: 8-Year Follow-up Data from 15 Spanish Centers

Tomas Jose Gonzalez-Lopez, Fernando Fernandez-Fuertes, Maria Cristina Pascual Izquierdo, PhD MD, Isabel Caparros, Silvia Bernat, Carmen Pastoriza, Maria Paz Martínez-Badas, Pável E Olivera, MD, Gonzalo Caballero, MD, Jose Angel Hernandez-Rivas, MD PhD, Daniel Martínez-Carballeira, MD, Inmaculada Soto Ortega, Gloria Perez Segura, Isabel Regalado, Blanca Sánchez-González, Isidro Jarque, Luis Javier garcia Frade, MD, Miguel A. Sanz

Blood (2019) 134 (Supplement_1): 2352.

https://doi.org/10.1182/blood-2019-129274

Published: 2019

Journal Articles

Genomic Landscape and Risk-Stratification for De Novo Acute Myeloid Leukemia with Normal Cytogenetics and No NPM1 or FLT3- itd Mutation

Blood (2019) 134 (Supplement_1): 1421.

https://doi.org/10.1182/blood-2019-127937

Published: 2019

Journal Articles

Predictive Factors of the Development of Leukemia in Patients with Transient Abnormal Myelopoiesis and Down Syndrome: The Jccg Study JPLSG TAM-10

Blood (2019) 134 (Supplement_1): 3833.

https://doi.org/10.1182/blood-2019-125465

Published: 2019

Journal Articles

Cellular Kinetics of CD19 Chimeric Antigen Receptor T Cells in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma

Caixia Li, Changfeng Zhang, PhD, Ying Zhang, Xiaoyan Lou, Jinfang Zhang, Jia Chen, MD, Xiaochen Chen, Liqing Kang, Jin Zhou, Xiangping Zong, Zhen Yang, Jiaqi Li, Wei Qi, Lei Yu, Depei Wu, MD PhD

Blood (2019) 134 (Supplement_1): 4097.

https://doi.org/10.1182/blood-2019-127928

Published: 2019

Journal Articles

Prognostic Effects of Pretreatment Statuses at Diagnosis in Patients with Chronic Myeloid Leukemia: Results of the New Target Observational Study 1

Takaaki ONO, MD PhD, Naoto Takahashi, MD PhD, Masahiro Kizaki, MD, Tatsuya Kawaguchi, MD, Ritsuro Suzuki, MD PhD, Kazuhito Yamamoto, Kazunori Ohnishi, MD, Tomoki Naoe, MD PhD, Itaru Matsumura, MD PhD

Blood (2019) 134 (Supplement_1): 4149.

https://doi.org/10.1182/blood-2019-122092

Published: 2019

Journal Articles

Splenic Marginal Zone Lymphoma: Risk of Transformation, Clinico-Biological Features at Transformation and Prognosis

Blood (2019) 134 (Supplement_1): 4015.

https://doi.org/10.1182/blood-2019-127199

Published: 2019

Journal Articles

Higher Expression of Nuclear Cereblon in Bone Marrow Biopsies of Patients with Multiple Myeloma Treated with Imids in the HOVON-87/Nmsg-18 Trial Is Associated with Longer PFS and OS

Ruth Wester, M Duin, King Hong Lam, MD PhD, Suzana Couto, Yan Ren, Maria Wang, Bronno Van Der Holt, PhD, Berna Berna Beverloo, PhD, Heleen Visser-Wisselaar, Alex Nigg, Anjan Thakurta, Sonja Zweegman, Annemiek Broyl, MD PhD, Pieter Sonneveld

Blood (2019) 134 (Supplement_1): 3071.

https://doi.org/10.1182/blood-2019-128584

Published: 2019

Journal Articles

The Broad Spectrum of TP53 Variants in CLL: NGS Analysis of 573 Pathogenic TP53 Variants

Blood (2019) 134 (Supplement_1): 3021.

https://doi.org/10.1182/blood-2019-130907

Published: 2019

Journal Articles

Impact of Comorbidities on Survival of Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Fernanda F Engelbrecht, Eliana C Miranda, PhD, Marcia Torresan Delamain, MD, Gislaine Borba Duarte, MD, Carmino Antonio Souza, MD PhD, Erich V De Paula, MD PhD, Katia B Pagnano, MD PhD

Blood (2019) 134 (Supplement_1): 2938.

https://doi.org/10.1182/blood-2019-129388

Published: 2019

Journal Articles

Analyses of Predictors of Durable Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Frontline or Second-Line Nilotinib

Jerald P. Radich, MD, Andreas Hochhaus, MD, Francis J. Giles, MD FRCPI, FRCPath, David M. Ross, MD, Giuseppe Saglio, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Dong-Wook Kim, Rafik Fellague-Chebra, MD, Manu Sondhi, MD PhD, Ranjan Tiwari, MSc, Kaushal Mishra, PhD, Francois-Xavier Mahon, MD PhD

Blood (2019) 134 (Supplement_1): 2932.

https://doi.org/10.1182/blood-2019-129393

Published: 2019

Journal Articles

Validation of Recently Proposed Risk and Prognostic Factors for Thrombotic Microangiopathy after Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Gi June Min, MD, Hee-Je Kim, MD PhD, Sung-Soo Park, MD, Silvia Park, Young-Woo Jeon, MD PhD, Seung-Ah Yahng, MD PhD, Seung-Hwan Shin, MD PhD, Jae-Ho Yoon, MD PhD, Sung-Eun Lee, MD, Byung Sik Cho, MD PhD, Ki-Seong Eom, MD PhD, Yoo-Jin Kim, MD PhD, Seok Lee, MD PhD, Chang-Ki Min, MD PhD, Seok-Goo Cho, MD PhD, Dong-Wook Kim, Jong-Wook Lee, MD PhD

Blood (2019) 134 (Supplement_1): 3260.

https://doi.org/10.1182/blood-2019-124275

Published: 2019

Journal Articles

ACUTE GRAFT Versus Host Disease 1990-2017: Reduced Incidence and Predictive Factors

Alessandra Di Francesco, MD, Andrea Bacigalupo, MD

Blood (2019) 134 (Supplement_1): 4526.

https://doi.org/10.1182/blood-2019-124843

Published: 2019

Journal Articles

Role of Blinatumomab in Minimal Residual Disease and Hematologic Relapsed/Refractory Adult Acute Lymphoblastic Leukemia Patients Treated over 5 Years. a Single Center Experience

Michela Ansuinelli, MD, Antonella Vitale, MD, Giovanna Pecoraro, MD, Saveria Capria, MD, Silvia Maria Trisolini, MD, Clara Minotti, MD, Claudio Cartoni, MD, Anna Maria Testi, MD, Maria Luisa Moleti, MD, Anna Paola Iori, MD, Walter Barberi, MD PhD, Irene Della Starza, PhD, Loredana Elia, Bs, Francesca Mancini, Maria Stefania De Propris, Anna Guarini, PhD, Sabina Chiaretti, MD PhD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 5121.

https://doi.org/10.1182/blood-2019-128156

Published: 2019

Journal Articles

Differential Alemtuzumab Dosage Effects in T-Cell Deplete Allogeneic Haematopoietic Stem Cell Transplants for Myeloid Malignancies- King's College Hospital London Experience

Varun Mehra, MBBS,MRCP,FRCPath, Daniele Avenoso, MD, Ximena Cabrera Castellano, Adrian Choy, Stefani Widya, Mili Shah, FRCPath, Shafqat Inam, MD, Shreyans Gandhi, MBBS,MDDNB,MRCP,FRCPath,MPhil, Austin Kulasekararaj, MD MRCP, FRCPath, Francesco Dazzi, PhD, Ghulam J. Mufti, MBBS, FRCP, FRCPath, DM, Antonio Pagliuca, MBBS, MA, FRCP, FRCPath, Hugues De Lavallade, Victoria Potter, MBBS, BSc, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 4622.

https://doi.org/10.1182/blood-2019-131239

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors

Lactate Dehydrogenase to Carboxyhemoglobin Ratio As a Biomarker of Heme Release to Heme Processing Is Associated with Higher Tricuspid Regurgitant Jet Velocity and Early Death in Sickle Cell Disease

Predictive Factors for Thrombopoietin Receptor Agonist Free Responses in Chronic ITP Patients: A Multicenter Retrospective Study with Long-Term Follow-up

Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Long-Term Follow up of the German Hodgkin Study Group (GHSG) HD14 Trial

RNA Sequencing in Childhood B-Lymphoblastic Leukemia Improves Molecular and Risk Assignment

Long Term Discontinuation of Eltrombopag after Remission in Primary Immune Thrombocytopenia: 8-Year Follow-up Data from 15 Spanish Centers

Genomic Landscape and Risk-Stratification for De Novo Acute Myeloid Leukemia with Normal Cytogenetics and No NPM1 or FLT3- itd Mutation

Predictive Factors of the Development of Leukemia in Patients with Transient Abnormal Myelopoiesis and Down Syndrome: The Jccg Study JPLSG TAM-10

Cellular Kinetics of CD19 Chimeric Antigen Receptor T Cells in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma

Prognostic Effects of Pretreatment Statuses at Diagnosis in Patients with Chronic Myeloid Leukemia: Results of the New Target Observational Study 1

Splenic Marginal Zone Lymphoma: Risk of Transformation, Clinico-Biological Features at Transformation and Prognosis

Higher Expression of Nuclear Cereblon in Bone Marrow Biopsies of Patients with Multiple Myeloma Treated with Imids in the HOVON-87/Nmsg-18 Trial Is Associated with Longer PFS and OS

The Broad Spectrum of TP53 Variants in CLL: NGS Analysis of 573 Pathogenic TP53 Variants

Impact of Comorbidities on Survival of Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Analyses of Predictors of Durable Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Frontline or Second-Line Nilotinib

Validation of Recently Proposed Risk and Prognostic Factors for Thrombotic Microangiopathy after Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

ACUTE GRAFT Versus Host Disease 1990-2017: Reduced Incidence and Predictive Factors

Role of Blinatumomab in Minimal Residual Disease and Hematologic Relapsed/Refractory Adult Acute Lymphoblastic Leukemia Patients Treated over 5 Years. a Single Center Experience

Differential Alemtuzumab Dosage Effects in T-Cell Deplete Allogeneic Haematopoietic Stem Cell Transplants for Myeloid Malignancies- King's College Hospital London Experience

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only